AR and posterior cortical atrophy: Androgen deprivation therapy (ADT) remains an effective non-surgical treatment for localized PCa; however, the majority of patients eventually progress to the castration-resistant prostate cancer (CRPC) stage through various resistance mechanisms, including androgen receptor (AR) amplification, AR splice variants, intratumoral androgen synthesis, and neuroendocrine differentiation [3,4,5,6].